Tricida - TCDA Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TCDA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TCDA, but not buy additional shares or sell existing shares.
View TCDA analyst ratings or view top-rated stocks.

5 brokerages have issued 1 year price objectives for Tricida's stock. Their TCDA share price forecasts range from $16.00 to $18.00. On average, they expect the company's share price to reach $17.00 in the next twelve months. This suggests a possible upside of 8,180.6% from the stock's current price.
View analysts price targets for TCDA or view top-rated stocks among Wall Street analysts.

Tricida's stock was trading at $9.56 at the start of the year. Since then, TCDA stock has decreased by 97.9% and is now trading at $0.2053.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023.
View our TCDA earnings forecast.

Tricida, Inc. (NASDAQ:TCDA) posted its earnings results on Monday, November, 14th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.10.

2 employees have rated Tricida Chief Executive Officer Gerrit Klaerner on Glassdoor.com. Gerrit Klaerner has an approval rating of 100% among the company's employees. This puts Gerrit Klaerner in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tricida investors own include Pfizer (PFE), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Atara Biotherapeutics (ATRA), bluebird bio (BLUE), Moderna (MRNA) and AT&T (T).

(TCDA) raised $175 million in an initial public offering on Thursday, June 28th 2018. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen acted as the underwriters for the IPO.

Tricida trades on the NASDAQ under the ticker symbol "TCDA."

Tricida's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include VR Adviser LLC (16.26%), BlackRock Inc. (6.64%), Commodore Capital LP (3.55%), Vanguard Group Inc. (2.99%), Citadel Advisors LLC (0.00%) and Point72 Asset Management L.P. (0.00%). Insiders that own company stock include Brian M Isern, Dawn Parsell Otto, Edward J Hejlek, Geoffrey M Parker, Gerrit Klaerner, Kurtis R Kurimsky, Orbimed Advisors Llc, Robert J Alpern, Robert Mckague, Sandra I Coufal, Venrock Healthcare Capital Par and Wilhelm Stahl.
View institutional ownership trends.

Shares of TCDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TCDA stock can currently be purchased for approximately $0.21.

Tricida (NASDAQ:TCDA) has a market capitalization of $11.43 million. The company earns $-176,570,000.00 in net income (profit) each year or ($2.36) on an earnings per share basis.

Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.tricida.com. The company can be reached via phone at (415) 429-7800 or via email at ir@tricida.com.